Recent health news highlights include China's approval of the first commercial brain-computer interface device, GSK's expanded RSV vaccine use in the U.S., Viatris' lawsuit settlement over Henrietta ...
Zacks Investment Research on MSN
GSK's RSV vaccine Arexvy wins FDA nod for high-risk younger adults
GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...
Respiratory syncytial virus (RSV) infection makes an impact on the epithelium that varies with age, promoting asthma in children and chronic obstructive pulmonary disease (COPD) in adults, according ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results